DNA Guide - Full Genome Molecular Diagnostics Platform
-
Upload
alice-rathjen-dna-guide -
Category
Investor Relations
-
view
110 -
download
1
description
Transcript of DNA Guide - Full Genome Molecular Diagnostics Platform
![Page 1: DNA Guide - Full Genome Molecular Diagnostics Platform](https://reader034.fdocuments.us/reader034/viewer/2022051412/54c6fe724a79590f458b45b2/html5/thumbnails/1.jpg)
Navigating Genetic Data
Privacy, Regulation and Ease of Use
Presentation @ Beyond the Genome, San Francisco, CA June 2011 DNA Guide, Inc. All rights reserved 2011
Alice Rathjen, President, Founder
![Page 2: DNA Guide - Full Genome Molecular Diagnostics Platform](https://reader034.fdocuments.us/reader034/viewer/2022051412/54c6fe724a79590f458b45b2/html5/thumbnails/2.jpg)
The Problem.. No Path to Market
Genetic Data Explosion Huge investment in
Sequencing Technologies
and Molecular Diagnostics
Personalized Medicine
R&D
Pharma /
Clinical
Trials
Consumers/
Patients IN
SU
RA
NC
E
Regulation, Privacy, Ease of Use
Health
Services
![Page 3: DNA Guide - Full Genome Molecular Diagnostics Platform](https://reader034.fdocuments.us/reader034/viewer/2022051412/54c6fe724a79590f458b45b2/html5/thumbnails/3.jpg)
Privacy
Biometric based security allow
written consent to evolve into
“real time” consent
• Use values in DNA sample to uniquely identify
each dataset
• Store and retrieve genetic data anonymously
• Perform audits, merge data
• Re-associate information throughout a
person’s lifetime
• Have variations for different uses
Raw DNA Values
DNA Security Token
![Page 4: DNA Guide - Full Genome Molecular Diagnostics Platform](https://reader034.fdocuments.us/reader034/viewer/2022051412/54c6fe724a79590f458b45b2/html5/thumbnails/4.jpg)
Regulation
www.DNAguide.com
![Page 5: DNA Guide - Full Genome Molecular Diagnostics Platform](https://reader034.fdocuments.us/reader034/viewer/2022051412/54c6fe724a79590f458b45b2/html5/thumbnails/5.jpg)
Solution is to Manage Interpretation and Access Down to the Base Pair Level
![Page 6: DNA Guide - Full Genome Molecular Diagnostics Platform](https://reader034.fdocuments.us/reader034/viewer/2022051412/54c6fe724a79590f458b45b2/html5/thumbnails/6.jpg)
DNA Guide Enables Dynamic Regulation & Compliance
Quality of Science
Medical Utility
Viewing Risk
(Graded) A,B,C,D,F
W = Withdrawn
I = Incomplete (by Scientific Community)
(by Health Care Providers/ Payers)
E = Everyone,
PG = Physician Guidance
R = Restricted
(Genetic Counselors, Ethics)
Category Rating
(Five Star Rating)
(Movie Rating)
![Page 7: DNA Guide - Full Genome Molecular Diagnostics Platform](https://reader034.fdocuments.us/reader034/viewer/2022051412/54c6fe724a79590f458b45b2/html5/thumbnails/7.jpg)
Ease of Use
(Mitochondria)
![Page 8: DNA Guide - Full Genome Molecular Diagnostics Platform](https://reader034.fdocuments.us/reader034/viewer/2022051412/54c6fe724a79590f458b45b2/html5/thumbnails/8.jpg)
Making the Complex - Simple
Highest Risk
Slightly Higher Risk
Normal
Lower Risk
Low Magnitude High Magnitude
![Page 9: DNA Guide - Full Genome Molecular Diagnostics Platform](https://reader034.fdocuments.us/reader034/viewer/2022051412/54c6fe724a79590f458b45b2/html5/thumbnails/9.jpg)
Quick Risk Assessment
![Page 10: DNA Guide - Full Genome Molecular Diagnostics Platform](https://reader034.fdocuments.us/reader034/viewer/2022051412/54c6fe724a79590f458b45b2/html5/thumbnails/10.jpg)
Converting the $1,000 Genome into the Two Minute Genome
![Page 11: DNA Guide - Full Genome Molecular Diagnostics Platform](https://reader034.fdocuments.us/reader034/viewer/2022051412/54c6fe724a79590f458b45b2/html5/thumbnails/11.jpg)
Removing the Genetic Education Barrier
Simple Graphic’s to explain genetic variation
Color code for Drug Response Information
Stop! (check details)
Warning (check details)
Go (normal dose)
![Page 12: DNA Guide - Full Genome Molecular Diagnostics Platform](https://reader034.fdocuments.us/reader034/viewer/2022051412/54c6fe724a79590f458b45b2/html5/thumbnails/12.jpg)
• Traditional model of laboratory services, proprietary algorithms,
legacy single chromosome browsers, no dynamic mechanism for
patient engagement.
• DNA Guide Advantages
– Patient engagement/empowerment focused mobile tools
– Leverage static nature of raw genome data vs public domain,
changing patent landscape, with ability to open up platform to
third party molecular diagnostics
– Provides foundation for patient centric health record
Competition
![Page 13: DNA Guide - Full Genome Molecular Diagnostics Platform](https://reader034.fdocuments.us/reader034/viewer/2022051412/54c6fe724a79590f458b45b2/html5/thumbnails/13.jpg)
DNA Guide Product Modules
DNA Security
Token
DNA Compass DNA Body
Use values within the DNA
sample to uniquely identify
every dataset. Token serves
as a dynamic or static IP
address - allowing every
person to become a node on
the network.
DNA Guide provides mobile dynamic
maps of entire genomes and can
perform spatial analysis across
multiple layers of different types of
genetic data.
DNA Guide’s DNA Body will
provide expression data,
medical records, and images to
be linked to a map of the human
body and to genomic location.
![Page 14: DNA Guide - Full Genome Molecular Diagnostics Platform](https://reader034.fdocuments.us/reader034/viewer/2022051412/54c6fe724a79590f458b45b2/html5/thumbnails/14.jpg)
Human Body Linked to Gene Expression
Electronic Health
Record
Grand SLAM
Long term plans -
expression data and
medical records
linked to a map of
persons body with
electronic health
record user account
derived from their
DNA.
Note: Image of body is
from Google body
browser but reflects DNA
Plans to incorporate map
of body as part of EMR
solution.
![Page 15: DNA Guide - Full Genome Molecular Diagnostics Platform](https://reader034.fdocuments.us/reader034/viewer/2022051412/54c6fe724a79590f458b45b2/html5/thumbnails/15.jpg)
Go to Market Strategy
Follow the Data into the Marketplace
Large Scale
Enterprise Software
Deployments
Cloud Services
Research
Consumers/
Patients P
ayo
rs, W
eln
es
s
$120 average per user per year plus transaction fees
Health
Services,
Government
Entities
Pharma,
Clinical Trials,
Molecular
Diagnosticss
![Page 16: DNA Guide - Full Genome Molecular Diagnostics Platform](https://reader034.fdocuments.us/reader034/viewer/2022051412/54c6fe724a79590f458b45b2/html5/thumbnails/16.jpg)
HEALTH SERVICE
PROVIDER
Assess Patient
Interact with payer to
determine eligibility
Prescribe test
Collect patient DNA sample
Submit DNA sample to lab
View lab information and
interpret results
Provide analysis and
recommendation to patient
Prescribe course of action.
Interface with pharma
regarding personalized
medicine
Interact with pharma with
clinical trial information
$120 avg per user/year subscription
PATIENT
Seeks Health Services
Submits DNA Sample
Views interpretation of results
from physician
Interact with payer regarding
reimbursement
Participation in Clinical Trials
Receives Drugs and Info from
Pharma
INSURANCE and PAYER ENTITIES
Require DNA tests for reimbursement of Rx and determine which genetic tests qualify for reimbursement
LAB
Process sample and results
Provide raw DNA data to
database storage for
interpretation
PHARMA/BIOTECH/R&D
INDUSTRY
Provide sample collection kits
and information regarding
personalized medicine
Interface with physician and
patients in clinical trials
Provide lab with new products
and services
Provide patient with retail info
DNA Guide
Genome Management Software
Information Flow
![Page 17: DNA Guide - Full Genome Molecular Diagnostics Platform](https://reader034.fdocuments.us/reader034/viewer/2022051412/54c6fe724a79590f458b45b2/html5/thumbnails/17.jpg)
$0
$50
$100
$150
$200
$250
$300
$350
$0
$50
$100
$150
$200
$250
$300
$350
FY1 FY2 FY3 FY4 FY5
Mill
ions
US Wellness Revenue
Revenue
Cost of Goods/Sale
G&A
OperatingProfit/(Loss)
Financials
Capital Efficient – Multiple Revenue Streams
![Page 18: DNA Guide - Full Genome Molecular Diagnostics Platform](https://reader034.fdocuments.us/reader034/viewer/2022051412/54c6fe724a79590f458b45b2/html5/thumbnails/18.jpg)
Alice Rathjen
President, Founder
William Kimmerly, Ph.D.
Chief Scientific Officer
Product Dev. Team
Xavier Thomas
Saw Yu Wai
Jeff Protentis (Sales)
ADVISOR
Mark S. Boguski, M.D., Ph.D.
Center for Biomedical Informatics
Harvard Medical School
Team
AWARD
![Page 19: DNA Guide - Full Genome Molecular Diagnostics Platform](https://reader034.fdocuments.us/reader034/viewer/2022051412/54c6fe724a79590f458b45b2/html5/thumbnails/19.jpg)
Funding/Milestones
Milestones Completed Human Genome Map deployed and tested on all major mobile platforms (iPAD, iPhone, Android, Blackberry)
Pilot Customer Projects (CysticFibrosis.com) Secured Mark Boguski, MD, Ph.D., Harvard as advisor. Discussion on Strategic partnerships underway with industry leaders (ESRI, Microsoft) Winner Kaufman Women in Science & Engineering Business Idea Competition 2011 World DNA Day Personalized Medicine Panel – Dalian, China 2011 Selected as “technology breakthrough” for Consumer Genetics Conference, Harvard Personalized Medicine Lab Symposium, Personalized Medicine World Conference Selected for Health 2.0 San Francisco “Launch”
Seed investment Finalize agreements with initial customer
Formalize strategic partnerships Apply for government grants Build out additional features Secure Series A Funding
Series A Top-tier management team recruited
Secure Major Enterprise Software Customers
![Page 20: DNA Guide - Full Genome Molecular Diagnostics Platform](https://reader034.fdocuments.us/reader034/viewer/2022051412/54c6fe724a79590f458b45b2/html5/thumbnails/20.jpg)
• Industry Transforming Technology
• Multiple Revenue Streams &
Capital Efficient • Visionary Team
Summary of DNA Guide Opportunity
Navigating Genetic Data Regulation, Privacy and Ease of Use
T
G
C
A
Contact: Alice Rathjen